11th Forum:

Healthcare and Life Sciences Industry: Preparing for 2019

 

December 18, 2018

12:30 PM – 4:00 PM

Yale Club Manhattan, Roof Dining Room & Terrace 22nd FL

 
 
Program

 

12:30-1:00 PM    Network Reception and Lunch

 

1:00-1:20 PM      Welcoming Speech & Opening Remark

"Healthcare and Lifesciences Current Trend and Forecasting 2019"

DoHyun Cho, PhD

CEO and President, W Medical Strategy Group / Chairman, New York Health Forum

Opening Remark

"Healthcare and Lifesciences: Forecasting the Future"

Jamie Metzl, PhD, JD

Senior Fellow, Atlantic Council

 

1:20-2:10 PM      Session 1 

"Key Trends in Therapeutic Deal Making"

Licensing in therapeutic companies is being used as a key growth strategy to improve their market position and strengthen their financial and business market values. Industry executives and experts will join as panels in this session to discuss about current deal trends and prospects in 2019.

 

  • Joe McMenamin, MD, JD, EVP, W Medical Strategy Group (Moderator)

  • Jeff Clark, MD, JD, Chief Business Officer, Enzychem Lifesciences

  • Sundeep Lal, PhD, MBA, CEO and Founder, BioConnexUs

  • Vincent Liu, PhD, Senior Advisor, Fosun Pharma

  • Young Moon, MBA (Vice President, BL&H USA)

 

2:10-3:10 PM      Session 2

"Real-World Evidence and the Transformational Role of Digital Health” 

This panel will discuss new digital health solutions for capturing and surfacing real-world evidence across siloed stakeholders. The panelists will discuss the application of data to impact patient care and the use of emerging technologies to provide the life sciences industry with insights that could transform current approaches to personalized medicine and clinical trials. Panelists with backgrounds in big data, AI, engineering and financial services, together with extensive clinical operations expertise, will discuss how digital health, machine learning, blockchain and asset-backed securities can reshape the life sciences sector through technology that delivers far more precise and actionable patient insights and provide alternative funding strategies as well.

 

  • Kimberly Ha, Founder, KKH Advisors (Moderator)

  • Ariel Katz, Chief Product Officer, H1

  • Kara Dennis, MBA, SVP and GM of Life Sciences, Clarify Health

  • Michelle Longmire, MD, CEO, Medable

  • Peter Lyons, Chief Innovation Officer, Atomic Capital

  • Robert Chu, CEO & Founder, Embleema

 

3:10-4:00 PM     Session 3

"Continued M&A Deals as the Recalibration of the Industry”

Mergers-and-acquisitions (M&A) activity has become the dominant force shaping the global pharmaceutical and biotech industries and the number keeps growing as a result of recent challenges including decrease in R&D productivity. This session will gather industry experts to discuss current trends and issues in M&A as it will improve the overall outlook of these sectors and continue to be a key growth strategy to acquire new drugs and technology.

 

  • Yiqin Shen (Senior Reporter, Mergermarket) (Moderator)

  • John Bradley, MD, Managing Director, Torreya Partners

  • John R. Lieberman, CPA, Managing Director, Perelson Weiner LLP

  • Sherman Williams, MBA, Director of Investment Banking, Chardan Capital Markets LLC

  • Sundeep Lal, PhD, MBA, CEO and Founder, BioConnexUs

 

4:00-4:20 PM     Award Ceremony & Networking

 

DoHyun Cho, PhD

CEO and President, W Medical Strategy Group | Chairman, New York Health Forum

 

DoHyun Cho is the founder, president, and CEO of a U.S. consulting company W Medical Strategy Group. W Medical Strategy Group has 5 subsidiaries including World Korean Medical Journal (publication), New York Health Forum (Conference), W MediTech (medical device distribution), W MedicalCare (global healthcare agency), and Green Alley (skincare product distribution). He is also the Board of Director for Enzychem Lifesciences. Before establishing W Medical Strategy Group, he was the director general of Korea Health Industry Development Institute (KHIDI) USA in New York for six years, a specialized agency of Ministry of Health of Republic of Korea. He also served as a Board of Director for KOCHAM (Korean American Chamber of Commerce) and was actively involved in a bio/pharma industry including serving as the Advisory Member for the Asia-Pacific Economic Cooperation (APEC) Harmonization Center, Korean government delegate for APEC Life Science Innovation Forum, Healthcare division representative for Korea-US Business Council, and etc.

Jamie Metzl, PhD, JD

Senior Fellow, Atlantic Council

 

Jamie Metzl is a technology futurist and geopolitical expert, novelist, entrepreneur, media commentator and Senior Fellow of the Atlantic Council. He previously served in the U.S. National Security Council, State Department, Senate Foreign Relations Committee and as a Human Rights Officer for the United Nations in Cambodia. He is also a former White House Fellow, Aspen Institute Crown Fellow and election monitor in Afghanistan and the Philippines. Currently, he is a member of the Council on Foreign Relations, faculty for Singularity University’s Exponential Medicine conference, the Korean Ministry of Trade, Industry and Energy’s Honorary Ambassador to North America and advisor to Walmart’s Future of Retail Policy Lab. As founder and co-chair of Partnership for a Secure America, he is additionally a board member of the International Center for Transitional Justice, American University in Mongolia and Brandeis International Center for Ethics, Justice, and Public Life.

Moderator: Joe McMenamin, MD, JD

EVP, W Medical Strategy Group

 

Joseph (Joe) P. McMenamin is an Executive Vice President and Chief Legal Officer with W Medical Strategy Group. He has more than 20 years of experience in defending pharmaceutical, medical device, and biotech companies in state and federal court. He also advises clients on managing risks related to telemedicine, corporate use of the internet, social media, communications between life science companies and physicians, compliance with FDA regulations.

Jeff Clark, MD, JD

Chief Business Officer, Enzychem Lifesciences

 

Jeff Clark is the Chief Licensing Officer at Enzychem Lifesciences, a Korean-based life sciences pharmaceutical company focusing on oncology, inflammatory and pulmonary diseases.  He develops the worldwide Intellectual Property (IP) Patent and Trademark portfolios.  He also collaborates and negotiates licensing and other agreements with third-parties regarding on-going clinical trials. He previously was an associate at the global law firm DLA Piper LLP (US), and was a clinical research fellow in the Molecular and Vascular Medicine Unit (Renal Division) at Beth Israel Deaconess Medical Center and a research fellow in the Cardiovascular Research Center at Massachusetts General Hospital.

Sundeep Lal, PhD, MBA

CEO and Founder, BioConnecxUs

 

Sundeep Lal is the CEO and Founder of BioConnexUS, LLC. He brings over twenty years of healthcare leadership experience in med-tech and pharma in the US and Emerging Markets with expertise in strategy, BD, hospital solutions sales, business model innovation, and new products at Medtronic & Merck. At Medtronic, Sundeep was based out of Singapore for six years covering Asia-Pacific. At Merck & Co, he was in global roles based on corporate HQ in NJ, USA.

Vincent Liu, PhD

Senior Advisor, Fosun Pharma

 

Vincent Liu is the Senior Advisor of Fosun Pharma. He worked in International Business Division and Wanbang Biopharmaceutical of Shanghai Fosun Pharmaceutical Group in 2009. His achievements including helping the company to raise a $500 million private equity fund from oversea and setting up two joint ventures with large US and Canadian companies in China, investment in healthcare service company in the US and completed several pharmaceutical business development transactions which could potentially bring to Chinese market total over $1 billion revenue product opportunities in the future.

Young Moon, MBA

Vice President, BL&H USA

 

Young Moon is the Vice President of BL&H USA. He graduated from the Engineering College of Seoul National University and received his M.S in Chemistry from KAIST and MBA from Yonsei University. He later became a chemical trader at LG International including a 6 year stint in Germany. Young started pharmaceutical consulting business after moving to the U.S in 2005. He was a Business Advisor for Hanmi Pharmaceuticals in Korea for 4 years, where he successfully mediated several global licensing deals. Currently, he is working as a business consultant for 20+ pharmaceutical / biotech companies. He is promoting 40 drug candidates from Korea for global licensing and he is mediating 5 licensing deals to Korea every year.

Moderator: Kimberly Ha

Founder, KKH Advisors

 

Kimberly Ha is the founder and CEO of KKH Advisors, a life sciences advisory firm. She was previously Senior Director at FTI Consulting, Healthcare Capital Markets Communications, where she advised a broad range of clients from Fortune 500 to early-stage development companies on business transformation, corporate and executive positioning, crisis and issues management, and financial communications. She is also a digital health advisor to Array Ventures, a VC fund based in San Francisco.

Ariel Katz

Chief Product Officer, H1

 

Ariel Katz is the Chief Product Officer of H1, the first company to arm healthcare and life science companies with on-demand, live insights from across the data universe to accelerate the discovery and development of therapies to fight diseases. He has previously worked at Greensightdata.com and was the co-founder of Labspot.io, a  curriculum management system for medical school student research, as well as the CEO and co-founder of ResearchConnection. At H1, he currently works to provide insights into thought leaders, scholarly content, academics and healthcare professionals to some of the largest and most influential global life science organizations.

Kara Dennis, MBA

SVP and GM of Life Sciences, Clarify Health

 

Kara Dennis is SVP and GM of Life Sciences for Clarify Health Solutions. Prior to Clarify, she was Managing Director of Mobile Health at Medidata Solutions, an industry-leading provider of SaaS solutions to the Life Sciences R&D industry. She led the creation of a comprehensive offering in mobile health, secured charter clients for offering development and launch, and built up a team to deliver and scale the offering. Her BU led the acquisition of a complementary cloud software company, and her client base grew to encompass several top-10 pharmaceutical companies. Before Medidata, she spent 4 years in McKinsey's healthcare practice, and corporate development for Ikaria, a private-equity backed biotech since acquired by Mallinckrodt.

Michelle Longmire, MD

CEO, Medable

 

Michelle Longmire is currently the Chief Executive Officer at Medable. She is a Stanford-trained physician-entrepreneur dedicated to transforming healthcare through innovation. She has a background in epigenetics, novel diagnostics, and imaging and she has published over 20 peer-reviewed articles and holds patents in machine learning as applied to mobile health applications. Her vision is to enable health technology to be as adaptive, seamless, and integrated as the human body.

Peter Lyons

Chief Innovation Officer, Atomic Capital

 

Peter Lyons is the Chief Innovation Officer at Atomic Capital, a digital investment banking platform that helps innovative companies raise capital from accredited investors globally. Prior to Atomic, he led ICT industry partnerships as Partnership Development Lead at the World Economic Forum, in addition to leading public-sector engagement as Senior Director at the GSM Association. He was also an equity research analyst on Wall Street covering emerging media and technology companies for institutional investors. With expertise in applying IoT, AI,and blockchain to private sector, environmental and social responsibility platforms, he is a contributor to Forbes, the World Economic Forum Agenda and SeekingAlpha.

Robert Chu

CEO and Founder, Embleema

 

Robert Chu is the CEO and CTO of Embleema, the first health records blockchain that seeks to empower patients and other data owners to securely share their health data. Prior to foundation of Embleema, he worked for IBM for more than 15 years, serving in key technical and management positions such as Global Wireless Solutions Executive in the U.S. and Director of Telecommunications for the Media & Utilities Sector of IBM France. He has also served as the President of IMS Health Asia Pacific & China and as the Senior Vice President of Global Technology Solutions for the firm’s affiliate, QuintilesIMS, where he was responsible for delivering SaaS solutions for the global healthcare and life sciences industries.

Moderator: Yiqin Shen

Senior Reporter, Mergermarket

 

Yiqin (Yee-chin) Shen is a Senior Reporter with Mergermarket and Dealreporter based in the New York office. Since joining in 2015, she has been covering US healthcare M&A, IPO and capital raise deals, as well as cross-border transactions across sectors involving Asia strategic investors and PE/VC firms. Her coverage also includes cross-border transaction regulatory review and policy development in the US and Asia. Prior to moving to the US, she interned at Mergermarket's Shanghai office for a year, after a stint at Reuters Shanghai bureau. Yiqin Shen holds a MS from Columbia Journalism School and a BA in Journalism from Fudan University.

John Bradley, MD

Managing Director, Torreya

 

John Bradley is the Managing Director at Torreya, where he works with the firm’s financing and M&A businesses. He has a vast network of relationships in the life sciences industry as well as with family offices and high net worth individuals worldwide. An expert in branded pharmaceuticals and drug delivery, he has raised over $500 million in public and private capital for many pharmaceutical, insurance, and technology companies. John has more than 40 years of corporate finance experience as an executive within both pharmaceutical companies and investment banks. Prior to joining Torreya, he was also a Founder and President of NYSE firm Bradley-Hummel & Co., and VP at Drexel Burnham & Co.

John R. Lieberman, CPA

Managing Director, Perelson Weiner LLP

 

John R. Lieberman is the Managing Director at Perelson Weiner LLP, where he works with biotechnology and pharmaceutical companies to implement financial controls, in addition to evaluating and working on private placements of publicly-traded securities or prior to an IPO. He has dedicated his practice of over 25 years to assist the owners of closely-held companies with business tax planning and risk management and high net worth individuals with their wealth management needs. He has extensive experience in a broad range of industries from the sports and entertainment industry to media, real estate, and healthcare companies both private and public. He is frequently solicited by the media to speak on tax issues.

Sherman Williams, MBA

Director of Investment Banking, Chardan Capital Markets

 

Sherman Williams is a Director of Investment Banking at Chardan Capital Markets, LLC where he advises public and private companies, investors, shareholders and strategic groups on financing and transactions. He was a former Naval Officer and is currently a Healthcare coverage investment banker focused on Biotechnology and Medical Technology. During his tenure as an Investment Banker, he has executed numerous M&A, Equity and Debt Capital Raise transactions at William Blair, Greenhill, and Chardan. He is a graduate of the U.S. Naval Academy and the University of Chicago Booth School of Business where he focused on Finance, Accounting, International Business, and Entrepreneurship.